Newborn screening for lysosomal storage disorders

Dietrich Matern

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Newborn screening is a public health programme aimed at identifying treatable conditions in pre-symptomatic newborns to avoid premature mortality, morbidity and disabilities. With the advent of successful treatment options for an increasing number of lysosomal storage disorders (LSDs), such as enzyme replacement or bone marrow transplantation, inclusion of these disorders into newborn screening programmes seems reasonable. However, the success of these programmes depends on the availability of testing methods that are suitable for population screening, have high sensitivity and a low false-positive rate. In recent years, two methods have been proposed for newborn screening of LSDs, which enable assessment of more than one LSD from a single blood spot sample. One applies tandem mass spectrometry, the other microbead array technology. Now, prospective studies are needed to determine the most effective approach to newborn screening that will identify those patients who require treatment. Conclusion: With the advent of high-throughput assays for the detection of LSDs, newborn screening for these disorders may soon become a reality. However, careful prospective studies are required to optimize this process before it is used on a larger scale.

Original languageEnglish (US)
Pages (from-to)33-37
Number of pages5
JournalActa Paediatrica, International Journal of Paediatrics
Volume97
Issue numberSUPPL. 457
DOIs
StatePublished - Apr 2008

Fingerprint

Newborn Infant
Prospective Studies
Premature Mortality
Tandem Mass Spectrometry
Bone Marrow Transplantation
Microspheres
Public Health
Technology
Morbidity
Enzymes
Therapeutics
Population

Keywords

  • Dried blood spots
  • Immunoquantification
  • Lysosomal storage disorders
  • Newborn screening
  • Tandem mass spectrometry

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Newborn screening for lysosomal storage disorders. / Matern, Dietrich.

In: Acta Paediatrica, International Journal of Paediatrics, Vol. 97, No. SUPPL. 457, 04.2008, p. 33-37.

Research output: Contribution to journalArticle

Matern, Dietrich. / Newborn screening for lysosomal storage disorders. In: Acta Paediatrica, International Journal of Paediatrics. 2008 ; Vol. 97, No. SUPPL. 457. pp. 33-37.
@article{5d6f01dfa9c44afe8c928e9f45b3ef03,
title = "Newborn screening for lysosomal storage disorders",
abstract = "Newborn screening is a public health programme aimed at identifying treatable conditions in pre-symptomatic newborns to avoid premature mortality, morbidity and disabilities. With the advent of successful treatment options for an increasing number of lysosomal storage disorders (LSDs), such as enzyme replacement or bone marrow transplantation, inclusion of these disorders into newborn screening programmes seems reasonable. However, the success of these programmes depends on the availability of testing methods that are suitable for population screening, have high sensitivity and a low false-positive rate. In recent years, two methods have been proposed for newborn screening of LSDs, which enable assessment of more than one LSD from a single blood spot sample. One applies tandem mass spectrometry, the other microbead array technology. Now, prospective studies are needed to determine the most effective approach to newborn screening that will identify those patients who require treatment. Conclusion: With the advent of high-throughput assays for the detection of LSDs, newborn screening for these disorders may soon become a reality. However, careful prospective studies are required to optimize this process before it is used on a larger scale.",
keywords = "Dried blood spots, Immunoquantification, Lysosomal storage disorders, Newborn screening, Tandem mass spectrometry",
author = "Dietrich Matern",
year = "2008",
month = "4",
doi = "10.1111/j.1651-2227.2008.00652.x",
language = "English (US)",
volume = "97",
pages = "33--37",
journal = "Acta Paediatrica, International Journal of Paediatrics",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "SUPPL. 457",

}

TY - JOUR

T1 - Newborn screening for lysosomal storage disorders

AU - Matern, Dietrich

PY - 2008/4

Y1 - 2008/4

N2 - Newborn screening is a public health programme aimed at identifying treatable conditions in pre-symptomatic newborns to avoid premature mortality, morbidity and disabilities. With the advent of successful treatment options for an increasing number of lysosomal storage disorders (LSDs), such as enzyme replacement or bone marrow transplantation, inclusion of these disorders into newborn screening programmes seems reasonable. However, the success of these programmes depends on the availability of testing methods that are suitable for population screening, have high sensitivity and a low false-positive rate. In recent years, two methods have been proposed for newborn screening of LSDs, which enable assessment of more than one LSD from a single blood spot sample. One applies tandem mass spectrometry, the other microbead array technology. Now, prospective studies are needed to determine the most effective approach to newborn screening that will identify those patients who require treatment. Conclusion: With the advent of high-throughput assays for the detection of LSDs, newborn screening for these disorders may soon become a reality. However, careful prospective studies are required to optimize this process before it is used on a larger scale.

AB - Newborn screening is a public health programme aimed at identifying treatable conditions in pre-symptomatic newborns to avoid premature mortality, morbidity and disabilities. With the advent of successful treatment options for an increasing number of lysosomal storage disorders (LSDs), such as enzyme replacement or bone marrow transplantation, inclusion of these disorders into newborn screening programmes seems reasonable. However, the success of these programmes depends on the availability of testing methods that are suitable for population screening, have high sensitivity and a low false-positive rate. In recent years, two methods have been proposed for newborn screening of LSDs, which enable assessment of more than one LSD from a single blood spot sample. One applies tandem mass spectrometry, the other microbead array technology. Now, prospective studies are needed to determine the most effective approach to newborn screening that will identify those patients who require treatment. Conclusion: With the advent of high-throughput assays for the detection of LSDs, newborn screening for these disorders may soon become a reality. However, careful prospective studies are required to optimize this process before it is used on a larger scale.

KW - Dried blood spots

KW - Immunoquantification

KW - Lysosomal storage disorders

KW - Newborn screening

KW - Tandem mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=41049088026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41049088026&partnerID=8YFLogxK

U2 - 10.1111/j.1651-2227.2008.00652.x

DO - 10.1111/j.1651-2227.2008.00652.x

M3 - Article

C2 - 18339185

AN - SCOPUS:41049088026

VL - 97

SP - 33

EP - 37

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - SUPPL. 457

ER -